Beaumont Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,222
Closed -$293K 68
2021
Q4
$293K Buy
1,222
+81
+7% +$20.8K 0.2% 62
2021
Q3
$323K Buy
1,141
+41
+4% +$13.4K 0.24% 56
2021
Q2
$381K Sell
1,100
-733
-40% -$222K 0.29% 52
2021
Q1
$513K Buy
1,833
+21
+1% +$5.66K 0.43% 41
2020
Q4
$443K Sell
1,812
-959
-35% -$247K 0.4% 40
2020
Q3
$786K Sell
2,771
-118
-4% -$32.9K 0.79% 28
2020
Q2
$772K Buy
2,889
+47
+2% +$14.1K 0.81% 28
2020
Q1
$899K Sell
2,842
-63
-2% -$19.1K 1.08% 24
2019
Q4
$862K Buy
+2,905
New +$806K 0.82% 40

Other funds holding BIIB

Beaumont Asset Management's BIIB Position: Q1 2022 in Review

Beaumont Asset Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 1,222 shares — an estimated $293K sold.

Beaumont Asset Management first reported a position in BIIB in Q4 2019 and held it in 9 quarters. The position peaked at $899K in Q1 2020. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • Beaumont Asset Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • Beaumont Asset Management sold 1,222 Biogen shares in Q1 2022, an estimated $293K.
  • Beaumont Asset Management first reported a position in Biogen in Q4 2019 and held it in 9 quarters.
  • Beaumont Asset Management's Biogen position peaked at $899K in Q1 2020.
  • 952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Beaumont Asset Management's 13F filing for Q1 2022, filed 2 May 2022.